American Association for Cancer Research
00085472can190255-sup-215885_3_supp_5641524_phkj4j.pdf (3.45 MB)

Supplementary Information from Roles and Regulation of Long Noncoding RNAs in Hepatocellular Carcinoma

Download (3.45 MB)
journal contribution
posted on 2023-03-31, 02:46 authored by Lee Jin Lim, Samuel Y.S. Wong, Feiyang Huang, Sheng Lim, Samuel S. Chong, London Lucien Ooi, Oi Lian Kon, Caroline G. Lee

This file contains 4 supplementary figures (Figure S1, Figure S2, Figure S3 and Figure S4), 9 supplementary tables (Table S1,Table S2, Table S3A, Table S3B, Table S3C, Table S3D, Table S3E, Table S4A and Table S4B) and references used in the tables.


National Medical Research Council



Next-generation sequencing has uncovered thousands of long noncoding RNAs (lncRNA). Many are reported to be aberrantly expressed in various cancers, including hepatocellular carcinoma (HCC), and play key roles in tumorigenesis. This review provides an in-depth discussion of the oncogenic mechanisms reported to be associated with deregulated HCC-associated lncRNAs. Transcriptional expression of lncRNAs in HCC is modulated through transcription factors, or epigenetically by aberrant histone acetylation or DNA methylation, and posttranscriptionally by lncRNA transcript stability modulated by miRNAs and RNA-binding proteins. Seventy-four deregulated lncRNAs have been identified in HCC, of which, 52 are upregulated. This review maps the oncogenic roles of these deregulated lncRNAs by integrating diverse datasets including clinicopathologic features, affected cancer phenotypes, associated miRNA and/or protein-interacting partners as well as modulated gene/protein expression. Notably, 63 deregulated lncRNAs are significantly associated with clinicopathologic features of HCC. Twenty-three deregulated lncRNAs associated with both tumor and metastatic clinical features were also tumorigenic and prometastatic in experimental models of HCC, and eight of these mapped to known cancer pathways. Fifty-two upregulated lncRNAs exhibit oncogenic properties and are associated with prominent hallmarks of cancer, whereas 22 downregulated lncRNAs have tumor-suppressive properties. Aberrantly expressed lncRNAs in HCC exert pleiotropic effects on miRNAs, mRNAs, and proteins. They affect multiple cancer phenotypes by altering miRNA and mRNA expression and stability, as well as through effects on protein expression, degradation, structure, or interactions with transcriptional regulators. Hence, these insights reveal novel lncRNAs as potential biomarkers and may enable the design of precision therapy for HCC.

Usage metrics

    Cancer Research



    Ref. manager